Press Releases

Media Inquiries - media@caredxinc.com
Date Title and Summary Additional Formats
Toggle Summary CareDx Expands into the Pre-Transplant Kidney Space through TX Connect
TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx’s focus on the patient journey SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary CareDx Reports Fourth Quarter and Full Year 2020 Results
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary Spotlight on CareDx’s Symposium at the Upcoming Cutting Edge of Transplantation (CEoT) Meeting
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,
View HTML
Toggle Summary CareDx to Report Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary CareDx to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
CareDx and Atara Biotherapeutics’ AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary CareDx Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary CareDx Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary CareDx Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Displaying 1 - 10 of 293 results